12.85 USD
-0.45
3.38%
At close May 14, 4:00 PM EDT
After hours
12.83
-0.02
0.16%
1 day
-3.38%
5 days
7.53%
1 month
-17.42%
3 months
-28.09%
6 months
-39.24%
Year to date
-39.39%
1 year
-48.83%
5 years
-27.61%
10 years
-11.38%
 

About: Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.

Employees: 13,500

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 8 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1.03% more ownership

Funds ownership: 99.39% [Q3] → 100.42% (+1.03%) [Q4]

5% less funds holding

Funds holding: 503 [Q3] → 478 (-25) [Q4]

17% less capital invested

Capital invested by funds: $17.5B [Q3] → $14.4B (-$3.05B) [Q4]

19% less repeat investments, than reductions

Existing positions increased: 166 | Existing positions reduced: 205

22% less first-time investments, than exits

New positions opened: 62 | Existing positions closed: 79

23% less funds holding in top 10

Funds holding in top 10: 13 [Q3] → 10 (-3) [Q4]

64% less call options, than puts

Call options by funds: $52.6M | Put options by funds: $145M

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$14
9%
upside
Avg. target
$16.88
31%
upside
High target
$22
71%
upside

8 analyst ratings

positive
50%
neutral
50%
negative
0%
Goldman Sachs
Matthew Sykes
43% 1-year accuracy
15 / 35 met price target
9%upside
$14
Neutral
Downgraded
29 Apr 2025
RBC Capital
Conor McNamara
10% 1-year accuracy
4 / 41 met price target
56%upside
$20
Outperform
Maintained
28 Apr 2025
Stifel
Daniel Arias
11% 1-year accuracy
2 / 19 met price target
9%upside
$14
Hold
Downgraded
28 Apr 2025
Barclays
Luke Sergott
33% 1-year accuracy
21 / 63 met price target
17%upside
$15
Overweight
Maintained
28 Apr 2025
Morgan Stanley
Tejas Savant
30% 1-year accuracy
6 / 20 met price target
17%upside
$15
Equal-Weight
Downgraded
28 Apr 2025

Financial journalist opinion

Based on 11 articles about AVTR published over the past 30 days

Neutral
PRNewsWire
1 week ago
Avantor® to Participate in Bank of America Securities 2025 Health Care Conference
RADNOR, Pa. , May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m.
Avantor® to Participate in Bank of America Securities 2025 Health Care Conference
Neutral
Zacks Investment Research
2 weeks ago
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
Negative
Benzinga
2 weeks ago
Avantor Analysts Cut Their Forecasts After Q1 Results
Avantor Inc AVTR reported in-line earnings for its first quarter on Friday.
Avantor Analysts Cut Their Forecasts After Q1 Results
Neutral
Seeking Alpha
2 weeks ago
Avantor: A Healthier Diagnosis As Expectations Cool
Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio.
Avantor: A Healthier Diagnosis As Expectations Cool
Neutral
Benzinga
2 weeks ago
Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift
Avantor Inc AVTR on Friday reported adjusted EPS of 23 cents in line with consensus.
Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift
Negative
Investopedia
2 weeks ago
Avantor Stock Plummets as Firm's CEO Set to Leave Amid Sales Slump, Outlook Cut
Avantor (AVTR) shares sank 16% Friday after the maker of lab chemicals and other life sciences products announced its CEO was resigning, reported weaker-than-expected net sales as government spending fell, and slashed its guidance.
Avantor Stock Plummets as Firm's CEO Set to Leave Amid Sales Slump, Outlook Cut
Neutral
Seeking Alpha
2 weeks ago
Avantor, Inc. (AVTR) Q1 2025 Earnings Call Transcript
Avantor, Inc. (NYSE:AVTR ) Q1 2025 Earnings Call April 25, 2025 8:00 AM ET Company Participants Allison Hosak - SVP of Global Communications and Brand Michael Stubblefield - President and CEO R. Brent Jones - EVP and CFO Conference Call Participants Michael Ryskin - Bank of America Securities Vijay Kumar - Evercore ISI Rachel Vatnsdal - J.P.
Avantor, Inc. (AVTR) Q1 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
2 weeks ago
Compared to Estimates, Avantor (AVTR) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Avantor (AVTR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Compared to Estimates, Avantor (AVTR) Q1 Earnings: A Look at Key Metrics
Positive
Zacks Investment Research
2 weeks ago
Avantor, Inc. (AVTR) Q1 Earnings Meet Estimates
Avantor, Inc. (AVTR) came out with quarterly earnings of $0.23 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago.
Avantor, Inc. (AVTR) Q1 Earnings Meet Estimates
Neutral
PRNewsWire
2 weeks ago
Avantor® Announces CEO Transition
Board initiates search process to identify next CEO RADNOR, Pa. , April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor.
Avantor® Announces CEO Transition
Charts implemented using Lightweight Charts™